Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome
Cells · 2026
DOI: 10.3390/cells15020211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Chuxiao Mao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 51063…. Hauptthemen laut MEDLINE: Glioma, Transcriptome, Basic Helix-Loop-Helix Proteins, Carcinogenesis. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Guangzhou Key Projects of Brain Science and Brain-Like Intelligence Technology, the Program for Guangdong Introducing Innovative and Entrepreneurial Teams, the Science and Technology Project in Guangzhou.
Abstract (Originalsprache)
Glioblastoma (GBM) remains incurable due to its invasive growth and therapeutic resistance. While the neurogenic transcription factor-mediated reprogramming of glioma cells has been reported, pharmacological reprogramming offers a promising alternative due to its potential advantages for clinical translation. Using phenotype-driven screening, we identified a multi-target small-molecule cocktail DLC79 (DAPT, LDN193189, CHIR99021, I-BET762, and Isx9) that effectively reprograms human glioma cells into neuron-like cells by activating endogenous ASCL1 (174.4-fold) and remodeling the transcriptional landscape. This conversion led to the strong upregulation of neuronal markers (e.g., MAP2 and GAD67) and suppression of glial identity. Functionally, DLC79 treatment inhibited glioma malignancy in vitro, impairing proliferation, migration, invasion, and clonogenicity. In a subcutaneous xenograft model, brief pretreatment with DLC79 significantly attenuated the tumorigenic potential of glioma cells, reducing tumor bioluminescence by 56% and tumor mass by 47%. Our study establishes pharmacological reprogramming as a promising anti-glioma strategy that leverages neuronal conversion to reduce oncogenic properties, thereby initiating a novel therapeutic paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China.
- Administrative Committee of Guangzhou-Hong Kong Intelligent Manufacturing Cooperation Zone, Guangzhou Development District, Guangzhou 510730, China.
- Orthopaedic Center, The Second Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang 524000, China.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou 51063…
- Chinese Medicine Guangdong Laboratory, Hengqin 519031, China.
ORCID-Profile: Gong Chen, Qingsong Wang
Förderung
- the Guangzhou Key Projects of Brain Science and Brain-Like Intelligence Technology
- the Program for Guangdong Introducing Innovative and Entrepreneurial Teams
- the Science and Technology Project in Guangzhou
- the Guangdong Province Science and Technology Project of China
- the National Natural Science Foundation of China
- the Natural Science Foundation of Guangdong Province of China
Zitieren
APA
Mao, C., Deng, Z., Chen, Z., Huang, L., Wang, C., Chen, G., & Wang, Q. (2026). Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. Cells. https://doi.org/10.3390/cells15020211
Vancouver
Mao C, Deng Z, Chen Z, Huang L, Wang C, Chen G, et al. Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. Cells. 2026. doi:10.3390/cells15020211
BibTeX
@article{Mao2026,
author = {Mao, Chuxiao and Deng, Zhancheng and Chen, Zhuming and Huang, Lirong and Wang, Caiyun and Chen, Gong and Wang, Qingsong},
title = {Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15020211}
}
EUVIMED